Refractory ITP at Seven Months: Sequencing Around a Pregnancy Plan
A first-grade teacher with steroid-dependent ITP wants the bleeding fixed without foreclosing a pregnancy she and her husband are planning for next year — and the two second-line options carry opposite timing risks for that plan.
Renata S., a 29-year-old first-grade teacher, spent last weekend noticing blood blisters along the inside of her cheek that she first mistook for a canker sore until three more appeared overnight. She was diagnosed with primary immune thrombocytopenia seven months ago after a routine physical turned up a platelet count of 22,000/µL and a workup found nothing else to explain it — no infection, no lupus serologies, no medication culprit. Prednisone brought her count comfortably above 100,000/µL within two weeks, and she tapered off it feeling like the problem was behind her. It came back within days of the last dose, and a second, longer steroid course has now failed the same way twice.
Today her platelet count is 8,000/µL, with new oral mucosal bleeding — the finding that turns this from a lab abnormality into a genuine short-term bleeding risk, since wet purpura is the traditional clinical marker for concern about more serious hemorrhage. She and her husband have been planning to start trying to conceive next year, a detail she raised herself before anyone asked, because she wants whatever comes next to actually fit that timeline rather than quietly foreclose it. She is seven months from diagnosis — inside the first year, the window in which roughly two-thirds of adults with newly diagnosed primary ITP either remit spontaneously or stabilize on minimal therapy. That figure is the quantified reason guidelines lean against jumping straight to splenectomy this early even in steroid-refractory disease, and the reason nobody in the room is treating her as a lifelong refractory patient after two failed tapers. The real question is which of the two standard second-line options, a TPO-receptor agonist or rituximab, actually clears the way for the pregnancy she wants rather than complicating it.
In clinic, five months short of a year
I'd start romiplostim today. It's fully reversible — if we stop it next year because she's ready to conceive, her count goes back to wherever her disease is at that point, which is at least a known, plannable state. The extension data behind RAISE and the romiplostim registry trials both show durable response with continued weekly dosing, and neither drug crosses into a pregnancy she hasn't started yet in a way we'd need to unwind months in advance.
If she'd told me she never wants to be pregnant, I'd weight this differently — the case for a TPO-RA leans specifically on its reversibility mattering to her timeline, not on it being intrinsically superior to rituximab.
I hear the reversibility argument, but reversible to what? Back onto a medication schedule she'd be carrying right up to the point she wants to stop everything. Patel and colleagues' five-year follow-up on rituximab in ITP found roughly one in five patients in sustained remission off all treatment — that's a real, if modest, shot at exactly what she said she wants: nothing in her system when she conceives.
Calling romiplostim the safer bridge assumes the bridge gets crossed cleanly. It doesn't address her actual stated goal, which isn't stability on a drug, it's being off every drug before she tries to get pregnant.
Both of you are arguing about which second-line drug, and I think the more useful frame is what happens in month twelve. She's not a lifelong steroid-refractory patient by definition yet — she's five months from the point where splenectomy, which has by far the best odds of a durable, drug-free remission, stops being premature. Start the TPO-RA now as the reversible bridge everyone agrees it is; revisit splenectomy specifically once she crosses twelve months, with vaccination started well ahead of that date regardless of which way she leans.
That doesn't resolve whether rituximab is ever the right call for her — it just means the decision she's actually facing today isn't a permanent one, and shouldn't be treated like it is.
Agreed: romiplostim started this week, with the pneumococcal, meningococcal, and Hib series begun in parallel so vaccination lead time is never again the reason a splenectomy decision gets delayed.
Splenectomy becomes the active recommendation, aimed at getting her drug-free well before she starts trying to conceive.
Rituximab moves back onto the table earlier, accepting the washout-timing tradeoff as the lesser problem against ongoing bleeding risk.